HOUSE OF REPRESENTATIVES

THE TWENTY-NINTH LEGISLATURE

REGULAR SESSION OF 2017

COMMITTEE ON HEALTH

Rep. Della Au Belatti, Chair

Rep. Bertrand Kobayashi, Vice Chair

Rep. Sharon E. Har	Rep. Chris Todd
Rep. Dee Morikawa	Rep. Andria P.L. Tupola
Rep. Marcus R. Oshiro

AMENDED NOTICE OF HEARING

DATE:	Thursday, March 16, 2017
TIME:	8:30 AM
PLACE:	Conference Room 329 State Capitol 415 South Beretania Street

A M E N D E D  A G E N D A

The following measure(s) has been DELETED from the agenda:  SB513, SB514 and SB997.

SB 503, SD2 (SSCR754) Status	RELATING TO VICTIMS OF SEXUAL VIOLENCE. Requires health insurance coverage for case management services by qualified mental health providers for victims of sexual violence and abuse.  Takes effect on 6/1/2050.  (SD2)	HLT, CPC, FIN
SB 505, SD1 (SSCR565) Status	RELATING TO HEALTH. Requires an opioid therapy informed consent process agreement to be executed between a patient and any prescriber of opioids within the State under certain conditions.  Requires the harm reduction services branch of the department of health to develop and make available a template of an opioid therapy informed consent process agreement for use in the State.  Specifies the contents of the template.  Requires all opioid therapy informed consent process agreements to be filed with the harm reduction services branch of the department of health for monitoring.  Establishes that prescribers who violate the mandatory opioid therapy informed consent process shall be subject to disciplinary action established by the Hawaii Medical Board or the State Board of Nursing.  Requires all prescribers who are authorized to prescribe opioids to register with Hawaii's electronic prescription accountability system.  Limits initial prescriptions for opioids and benzodiazepines to a maximum of seven consecutive days with certain exceptions.  Effective 7/1/2050.  (SD1)	HLT, CPC
SB 514, SD1 (SSCR556) Status	RELATING TO HEALTH. Authorizes pharmacists to administer the human papillomavirus, Tdap (tetanus, diphtheria, pertussis), meningococcal, or influenza vaccine to persons between eleven and seventeen years of age.  Specifies requirements pharmacists must meet prior to administering the human papillomavirus, Tdap (tetanus, diphtheria, pertussis), meningococcal, or influenza vaccine.  (SD1)	HLT, CPC
SB 513, SD1 (SSCR555) Status	RELATING TO CONTRACEPTIVE SUPPLIES. Authorizes pharmacists to prescribe and dispense self-administered hormonal contraceptive supplies to patients, regardless of a previous prescription from an authorized prescriber.  Specifies requirements pharmacists must meet prior to prescribing and dispensing contraceptive supplies.  Enables pharmacists to be reimbursed for prescribing and dispensing contraceptive supplies.  (SD1)	HLT, CPC
SB 384, SD2 (SSCR866) Status	RELATING TO PRESCRIPTIVE AUTHORITY FOR CERTAIN CLINICAL PSYCHOLOGISTS. Authorizes and establishes procedures and criteria for prescriptive authority for clinical psychologists who meet specific education, training, and registration requirements, including requiring prescribing psychologists to adhere to all applicable statutory regulations.  Requires the board of psychology to report to the legislature prior to the regular session of 2021.  Takes effect on January 7, 2059.  Sunsets August 31, 2025.  (SD2)	HLT, FIN
SB 997, SD1 (SSCR892) Status	RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT. Updates the Uniform Controlled Substances Act to make it consistent with amendments in federal controlled substances law as required under the authority to schedule controlled substances.  Takes effect on 1/7/2059.  (SD1)	HLT, JUD
SB 1312, SD2 (SSCR813) Status	RELATING TO THE LICENSURE OF MIDWIVES. Establishes the board of midwifery to regulate the practice of midwifery by certified midwives and certified professional midwives.  Requires licensing of certified midwives and certified professional midwives to commence beginning on July 1, 2020.  Requires the department of commerce and consumer affairs to convene a working group of interested stakeholders and submit a report to the legislature.  Effective July 1, 2050.  (SD2)	HLT, CPC, FIN

DECISION MAKING TO FOLLOW

Persons wishing to offer comments should submit testimony at least 24 hours prior to the hearing.  Testimony should indicate:

· Testifier's name with position/title and organization;

· The Committee(s) to which the comments are directed;

· The date and time of the hearing; and

· Measure number. 

While every effort will be made to incorporate all testimony received, materials received on the day of the hearing or improperly identified or directed, may be distributed to the Committee after the hearing.

Submit testimony in ONE of the following ways:

PAPER:  15 copies (including an original) to Room 403 in the State Capitol;

FAX:       For testimony less than 5 pages in length, transmit to 808-586-6311 (Oahu) or 1-800-535-3859 (for Neighbor Islander without a computer to submit testimony through e-mail or the Web); or

WEB:     For testimony less than 10MB in size, transmit from http://www.capitol.hawaii.gov/submittestimony.aspx.

Testimony submitted will be placed on the legislative website.  This public posting of testimony on the website should be considered when including personal information in your testimony.

If you require special assistance or auxiliary aids and/or services to participate in the House public hearing process (i.e., sign or foreign language interpreter or wheelchair accessibility), please contact the Committee Clerk at 586-9425 or email your request for an interpreter to [email protected] at least 24 hours prior to the hearing for arrangements.  Prompt requests submitted help to ensure the availability of qualified individuals and appropriate accommodations.

Selected meetings are broadcast live.  Check the current legislative broadcast schedule on the "Capitol TV" website at www.capitoltv.org or call 536-2100.

________________________________________

Rep. Della Au Belatti

Chair